The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.

ABSTRACT:

Objectives

To evaluate the efficacy of immuno-oncology combinational therapy (IOCT) versus monotherapy with programmed cell death 1 (PD-1) or PD-ligand 1 (PD-L1) inhibitors or conventional therapies, i.e., non-IOCT, in patients with advanced solid tumors.

Methods

We systematically searched the PubMed, Embase, and Cochrane Library databases from January 2015 to October 2018 for eligible studies. We included randomized trials of IOCT with available hazard ratios (HR) for death. The random effects model was used to calculate pooled HR for death; heterogeneity was assessed using I ² statistics. The main outcome measure was overall survival (OS).

Results

After screening 483 relevant articles, we identified twelve trials comprising 5388 patients for quanti

SUBMITTER: Nie RC 

PROVIDER: S-EPMC7225910 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature